E-grāmata: International Review of Neurobiology

CONTRIBUTORS		ix
GABAA Receptor Structure-Function Studies: A Reexamination in Light of New Acetylcholine Receptor Structures
MYLES H. AKABAS
I. Overview		2	(1)
II. Subunits, Cloning, Topology, and Assembly		3	(2)
III. Receptor Kinetics		5	(1)
IV. Channel Characteristics: Selectivity and Conductance		6	(1)
V. SCAM and Channel Structure-Function Relationships		7	(1)
VI. Overview of High-Resolution Structures of the Homologous ACh Receptor		8	(1)
VII. The Membrane-Spanning Domain Structure		9	(15)
VIII. AChBP Structure and the GABA Binding Sites		24	(4)
IX. The Interface Between the Extracellular and Membrane-Spanning Domains: How Does Transduction Work?		28	(2)
X. Conclusions		30	(1)
References		31	(15)
Dopamine Mechanisms and Cocaine Reward
AIKO IKEGAMI AND CHRISTINE L. DUVAUCHELLE
I. Introduction		46	(1)
II. Basic Pharmacology of Cocaine		47	(1)
III. Monoamine Transporters		48	(5)
IV. Nucleus Accumbens Dopamine		53	(2)
V. Prefrontal Cortex Dopamine		55	(4)
VI. Midbrain Dopamine Neurons		59	(1)
VII. Phasic and Tonic Dopamine Release		60	(1)
VIII. Dopamine Receptors		61	(1)
IX. Striatal Medium Spiny Neurons		62	(1)
X. Dopamine and Intracellular Cascades		63	(2)
XI. Neural Basis of Associative Learning		65	(1)
XII. Midbrain Dopamine Neurons and Associative Learning		66	(2)
XIII. Drug Addiction and Learning		68	(1)
XIV. Cocaine-Associative Learning		69	(8)
XV. Summary		77	(3)
References		80	(15)
Proteolytic Dysfunction in Neurodegenerative Disorders
KEVIN ST.P. MCNAUGHT
I. Introduction		95	(3)
II Proteolysis in the Central Nervous System		98	(3)
III. Parkinson's Disease		101	(5)
IV. Alzheimer's Disease		106	(2)
V. Amyotrophic Lateral Sclerosis		108	(1)
VI. Polyglutamine Repeat Diseases		109	(1)
VII. Prion Diseases		110	(1)
VIII. Conclusion		111	(1)
References		112	(9)
Neuroimaging Studies in Bipolar Children and Adolescents
RENE L. OLVERA, DAVID C. GLAHN, SHEILA C. CAETANO, STEVEN R. PLISZKA, AND JAIR C. SOARES
I. Introduction		121	(1)
II. Background		122	(1)
III. Methodology		123	(1)
IV. Neuropsychological Abnormalities in Bipolar Disorder		123	(2)
V. Brain Imaging Findings in Adult Patients		125	(8)
VI. Brain Imaging Findings in Children and Adolescents		133	(3)
VII. Summary		136	(1)
References		137	(10)
Chemosensory G-Protein-Coupled Receptor Signaling in the Brain
GEOFFREY E. WOODARD
I. Introduction		147	(1)
II. Chemosensing G-Protein-Coupled Receptors in the Brain		148	(6)
References		154	(6)
Disturbances of Emotion Regulation after Focal Brain Lesions
ANTOINE BECHARA
I. Definitions		160	(1)
II. The Neuroanatomy of Emotions and Feelings		161	(2)
III. Disturbances of Emotional Experience After Focal Brain Damage		163	(10)
IV. Developmental Versus Adult-Onset Brain Damage		173	(2)
V. Neural Mechanisms of Emotional Control		175	(2)
VI. Emotion, Cognition, and Social Behavior		177	(10)
VII. Conclusion		187	(2)
References		189	(11)
The Use of Caenorhabditis elegans in Molecular Neuropharmacology
JILL C. BETTINGER, LUCINDA CARNELL, ANDREW G. DAVIES, AND STEVEN L. MCINTIRE
I. Ivermectin		200	(3)
II. Fluoxetine		203	(2)
III. Alcohol		205	(3)
References		208	(5)
INDEX		213	(6)
CONTENTS OF RECENT VOLUMES		219

Professor Peter Jenner is a specialist in preclinical aspects of neurodegenerative diseases, notably Parkinsons disease. He has spent the major part of his career at Kings College London where he was Head of Pharmacology for 14 years before returning to his research roots and subsequently becoming Emeritus Professor of Pharmacology. Peter has expertise in drug metabolism and pharmacokinetics but neuropharmacology based on functional models of neurodegenerative diseases has formed the major focus of his work. Peter holds a BPharm, PhD and DSc degree from the University of London. He has published well over 1000 articles with more than 700 peer reviewed papers. He is a Fellow of the Royal Pharmaceutical Society, the British Pharmacological Society, the Royal Society of Medicine and of Kings College London. Peter was recently honoured with a Doctor Honoris Causa degree from Carol Davila University of Medicine and Pharmacy, Bucharest and made an Honorary Fellow of The British Pharmacological Society for his contribution to research in to movement disorders.

Peter has worked closely with the pharmaceutical industry for many years and acts as an adviser and consultant to both major pharma and biotech companies. He has a wide knowledge of the drug discovery and drug development process and has been involved from molecule synthesis through to drug registration for use in man. Peter was the Founder, Director and Chief Scientific Officer of Proximagen, a biotech focussed on the treatment and cure of neurodegenerative diseases that was listed on AIMs and subsequently purchased by a US based healthcare company. He is a regular speaker at international meetings and also takes time to speak at Parkinsons disease patient-carer groups across the UK.